Commercial Strategy
Developing strategies and solutions for products across the lifecycle to optimize product profiles, drive early commercial success, and maximize product value
Sell-Side Partnering
Securing non-dilutive capital and pharma partners' resources for clients
Business Development
Build the value story, construct high-impact marketing materials, identify optimal strategic partners, conduct outreach to global industry network, and facilitate due diligence and deal closing
Transaction Advisory
Create deal tension through a structured process, conduct asset valuation and deal comparables analyses to optimize financial terms, and leverage substantial LifeSci transaction experience to support negotiations
Buy-Side Partnering
Securing assets or companies to bolster clients' product portfolios
Search & Evaluation
Utilize client parameters of interest to identify opportunities, prioritize/tier identified opportunities, and leverage BD expertise and network to vet availability / transactability
Commercial Due Diligence
Evaluate the scientific, regulatory, and commercial merits of potential opportunities – backed by primary research (e.g., physicians, payers, patients) – and leverage LifeSci platform to understand investor sentiment on opportunities
Proven Success
We leverage LifeSci’s global industry relationships and decades of transaction experience to drive our clients’ business development initiatives
Global industry network, including over 5,000 contacts
Experience across global markets (U.S., EU, Asia, LATAM, MENA)
Highlighted Deals
2022
Option to License
~$27M Equity Investment
2021
Exclusive License
$420M
2021
Exclusive China License
Undisclosed
2021
Exclusive License
Undisclosed
2019
Exclusive License
Undisclosed
2019
Exclusive License
$568M
2019
Option to License
$481M
2018
Acquisition
$420M
2018
Exclusive China License
$9.5M
2018
Product Acquisition
$30M
2016
Exclusive License
$469M
2016
Exclusive License
$230M
2016
Exclusive License
$100M
2015
Distribution Agreement
Undisclosed
2015
Product Acquisition
Undisclosed
2015
Exclusive License
$85M
2015
M&A
$30M
2014
Exclusive China License
$9M
2014
Exclusive License
Undisclosed
2013
Exclusive License
$121M
2012
Exclusive License
Undisclosed
2010
Exclusive License
$625M
2009
Exclusive License
$200M
2008
Exclusive License
$385M
Want to learn more?
We bring decades of experience to your challenges with a team that is uniquely designed to meet your needs